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Abstract
Background and Aims: Inclusion of the mesentery during resection for colorectal cancer is 
associated with improved outcomes but has yet to be evaluated in Crohn’s disease. This study 
aimed to determine the rate of surgical recurrence after inclusion of mesentery during ileocolic 
resection for Crohn’s disease.
Methods: Surgical recurrence rates were compared between two cohorts. Cohort A  [n  =  30] 
underwent conventional ileocolic resection where the mesentery was divided flush with the 
intestine. Cohort B [n = 34] underwent resection which included excision of the mesentery. The 
relationship between mesenteric disease severity and surgical recurrence was determined in a 
separate cohort [n = 94]. A mesenteric disease activity index was developed to quantify disease 
severity. This was correlated with the Crohn’s disease activity index and the fibrocyte percentage 
in circulating white cells.
Results: Cumulative reoperation rates were 40% and 2.9% in cohorts A  and B [P  =  0.003], 
respectively. Surgical technique was an independent determinant of outcome [P = 0.007]. Length 
of resected intestine was shorter in cohort B, whilst lymph node yield was higher [12.25 ± 13 versus 
2.4 ± 2.9, P = 0.002]. Advanced mesenteric disease predicted increased surgical recurrence [Hazard 
Ratio 4.7, 95% Confidence Interval: 1.71–13.01, P = 0.003]. The mesenteric disease activity index 
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correlated with the mucosal disease activity index [r = 0.76, p < 0.0001] and the Crohn’s disease 
activity index [r = 0.70, p < 0.0001]. The mesenteric disease activity index was significantly worse 
in smokers and correlated with increases in circulating fibrocytes.
Conclusions: Inclusion of mesentery in ileocolic resection for Crohn’s disease is associated with 
reduced recurrence requiring reoperation.
Key Words:  Crohn’s disease; mesentery; ileocolic resection; recurrence; fibrocyte
1. Introduction
Mesenteric-based surgical techniques are the basis of good quality 
surgery in the management of colorectal cancer.1,2 Although it is sug-
gested that they may lead to improved outcomes following surgery 
in Crohn’s disease, they have yet to be evaluated in this context.1,3 
The surgical approach to Crohn’s disease has developed relatively 
little since its first description. Earlier approaches emphasised ile-
ocolic bypass.4 This was followed by radical and thereafter by con-
servative intestinal resection.4,5 Technical conservatism extended to 
the mesentery and, rather than mobilise and excise it as one might 
do for colorectal cancer, the mesentery is normally divided flush with 
the intestine and thus retained.
Conservative approaches to the mesentery have dominated the 
surgical management of Crohn’s disease,2,4,5 despite repeated rec-
ommendations that the mesentery be resected.6–8 This inconsistency 
is explained as follows. Until recently, descriptions of core mesen-
teric anatomy were inaccurate.1–3 This has particular implications 
for complex intestinal surgery where perforation, fistulation, and 
disease spread [common features of advanced Crohn’s disease] 
lead to adherence of normally separate organs.9,10 Unless one has a 
clear understanding of mesenteric anatomy, safe unravelling of the 
components of an inflammatory mass is challenging. The second 
explanation lies in the fact that the mesentery in Crohn’s disease is 
characteristically thickened and bleeds heavily if divided across.4,11,12 
Unless one has a failsafe mechanism for haemostatic division of the 
Crohn’s mesentery, rates of blood loss and associated complications 
increase.
Recent advances in our understanding of mesenteric anat-
omy mean that techniques are available by which the mesentery in 
Crohn’s disease may be safely separated from adjacent structures, 
and haemostatically divided.1–3 Clarification of the anatomy of the 
mesentery means one can better separate the components of an 
inflammatory mass, with minimal trauma to each. Following this, 
the intestine and mesentery can be fully detached from the retro-
peritoneum in a manner that facilities safe vascular division and 
disconnection.1–3
At present, 80% of patients with Crohn’s disease will require at 
least one operation13 and 40% will require multiple surgeries.13,14 
Most recurrences occur within 36 months of surgery.15–18 Over the 
long term, surgical recurrence rates appear to decrease.17,19,20 The 
introduction of biologic and immunomodulatory agents has had 
relatively limited impact on rates of surgery.21,22 As a result, there is 
a need to refresh our surgical approach to Crohn’s disease. With this 
in mind, the objective of this study was to determine rates of surgi-
cal recurrence in patients undergoing surgery for ileocolic Crohn’s 
disease, in which the mesentery was included as part of the resection. 
These were compared with surgical recurrence rates in a cohort of 
patients who underwent conservative ileocolic resection. Mesenteric 
mesenchymal abnormalities were characterised in patients in whom 
the mesentery was included in the resection.
2. Materials and Methods
Ethical approval with informed consent was obtained from the HSE 
Mid-Western Regional Hospital Research Ethics Committee.
2.1. Cohorts examined
The incidence of recurrent Crohn’s disease requiring surgical inter-
vention [i.e. surgical recurrence] was compared between two cohorts 
in a population-based study. Cohort A  [a historical cohort] com-
prised 30 consecutive patients undergoing ileocolic resection for a 
Crohn’s-related indication during the interval from January 2004 
to April 2010 [mean follow-up time: 69.9  ±  48.47  months] in 
University Hospital Limerick [UHL, then called the Mid-Western 
Regional Hospital]. In Cohort A, the mesentery was divided flush 
with the region of intestine to be resected [Figure  1A]. This was 
achieved by dividing the mesentery between arterial clamps, or by 
use of a haemostatic vessel-sealing device. The proximal and dis-
tal resection margins were positioned at levels where the ileum and 
colon [respectively] were macroscopically normal, regardless of the 
appearance of the mesentery. Before August 2010 all resections were 
conducted in this manner.
In Cohort B [n  =  34], the mesentery was fully mobilised and 
partially excised [Figure  1B]. A  description of the surgical tech-
nique is provided in Supplementary Methods, available at ECCO-
JCC online. The mesentery was fully detached and the ileal division 
made just proximal to the mesenteric transition zone [Figure 1C–F; 
Supplementary Figure  1, available at ECCO-JCC online]. From 
this level, the mesentery was divided as close to the mesenteric root 
region as was deemed safe. The mesenteric division was then con-
tinued away from the root region to the colon, which was divided 
at a level where both colon and contiguous mesentery were nor-
mal in appearance. The technique of haemostatic mesenteric divi-
sion using Kocher clamps is described in Supplementary Methods 
[Supplementary Figure  2, available at ECCO-JCC online]. After 
August 2010, 34 consecutive resections for Crohn’s disease were 
prospectively conducted using this approach [mean follow-up time: 
51.7  ±  20.98  months] in University Hospital Limerick. In both 
cohorts, reoperations for management of a postoperative compli-
cation were not considered as a ‘reoperation for a Crohn’s-related 
indication’ and thus were not included in comparisons of surgical 
recurrence rates.
The above cohorts comprised patients with ileocolic Crohn’s dis-
ease. Cohort C [n = 94, Supplementary Table 1, available at ECCO-
JCC online] was an additional cohort included to determine the 
relationship between histological fat wrapping [a feature of severe 
mesenteric disease] and surgical recurrence in all intestinal forms of 
Crohn’s disease. All Crohn’s disease patients who underwent consec-
utive resections, irrespective of disease location, from January 2000 
to August 2012 in UHL, were included in Cohort C. Fat wrapping 
was considered present if greater than 50% of the bowel circumfer-
ence was covered by mesenteric adipose tissue.23–25
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In all cases, diagnosis of Crohn’s disease was based on a com-
bination of radiological, endoscopic and pathological findings. 
Retrieved data are listed in Supplementary Methods [available at 
ECCO-JCC online: see section on demographics]. All specimens 
[i.e. endoscopic and surgical] were examined by a team of pathol-
ogists who reviewed and discussed each specimen together. All 
patients were managed pre- and postoperatively by the same team of 
gastroenterologists. A greater number of patients in Cohort B were 
treated with preoperative biologics before [but not after] index sur-
gery [Table 2]. Postoperatively, 20% and 21% of patients were con-
sidered at high risk of postoperative surgical recurrence and were 
placed on prophylactic medication, in cohorts A and B respectively 
[Table 2]. Patients developing recurrent disease were managed using 
a step-up approach.
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Figure 1. [A] [Left] Right colon and terminal ileum and line demonstrating mesenteric division flush with the intestinal margin, i.e. mesentery retained. [Right] 
Postoperative specimen following conventional resection and division of mesentery flush with the intestine. Both images are representative of conventional 
resection for Crohn’s disease. [B] [Left] Right colon, terminal ileum, and mesentery, with a line demonstrating a mesenteric division wide of the intestinal 
margin, i.e. mesentery excised. [Right] Postoperative specimen following mesocolic excision. The entire right mesocolon is evident. A substantial volume of 
small intestinal mesentery is apparent. Both images are representative of concept of mesenteric resection for Crohn’s disease. [C] Mesenteric transition zone in 
a postoperative specimen following resection for ileocolic Crohn’s disease. [D] Mesenteric transition zone at a skip lesion. [E] Mucosal transition zone adjacent 
mesenteric transition zone in specimen in [C]. [F] Mucosal transition zone adjacent mesenteric transition zone in specimen in [D]. [G] Kaplan-Meier estimates 
demonstrating the cumulative incidence of reoperation for a Crohn’s-related indication in patients in Cohort A  [i.e. mesentery excluded] and Cohort B [i.e. 
mesentery included]. Estimates were compared using log-rank analysis.
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Management was guided using a multidisciplinary team [MDT] 
approach and was based on MDT consensus. Indications for surgery 
included: [i] development of a complication arising due to Crohn’s 
disease [i.e. obstruction, perforation, fistulation]; and [ii] failure of 
symptoms to improve on medical therapy.
2.2. Mesenteric, mucosal and Crohn’s disease 
activity indices
Resection specimens from Cohort B were examined for mesen-
teric and mucosal disease, and a separate index was generated to 
quantify each of these. The ‘mesenteric disease activity index’ was 
developed using fat wrapping and mesenteric thickening as sever-
ity parameters [Figure 2A–C, Table 1A]. Fat wrapping was graded 
according to the proportion of intestinal circumference affected 
[Figure 2A, B, Table 1A]. Mesenteric thickening was graded based on 
appearance of vascular and avascular mesenteric regions [Figure 2C, 
Table 1A]. In mild mesenteric disease, these could be differentiated 
[Figure 2C].26,27 In moderate mesenteric disease, thickening was con-
fined to vascular pedicles [Figure 2C]. In severe disease, thickening 
also involved avascular regions. As a result, pedicular and interpedic-
ular regions could not be differentiated [Figure 2C].
A ‘mucosal disease activity index’ was developed using oedema, 
ulceration [aphthous, linear, or confluent], stricture, and fistula as 
severity parameters [Figure 2D, Table 1B]. Points were attributed to 
each finding and the final score was the sum of all points. Mesenteric 
and mucosal disease activity scores were generated by examination 
of surgical specimens immediately following resection. Mesenteric, 
mucosal, and preoperative Crohn’s Disease Activity Index [CDAI] 
were recorded by separate investigators and correlated [see below].
2.3. Light and scanning electron microscopic 
characterisation of the mesentery in Crohn’s disease
In all patients in Cohort B, sections were prepared for light micro-
scopic examination and stained using haematoxylin and eosin as 
previously described.28 The thicknesses of [i] surface mesothelial/
connective tissue complex, and [ii] connective tissue septations, 
were determined in regions of mild, moderate, and severe mesen-
teric disease. Adipocyte cell numbers were determined in each region 
(manually counted cells in 10 high-powered fields [HPF] and then 
averaged). The mesentery, adjacent intestine, and intervening zone 
of intersection were examined using scanning electron microscopy 
[SEM] in cadavers to establish a normal reference [n  =  5] and in 
randomly chosen patients from Cohort B [n  =  5] [Supplementary 
Methods, available at ECCO-JCC online]. SEM analysis was per-
formed using a Hitachi S2600N Variable Pressure Scanning Electron 
Microscope [Hitachi, Tokyo, Japan].
2.4. Quantification of fibrocyte levels in peripheral 
circulation
As fibrocytes are circulating progenitors that can differentiate into 
either fibroblasts or adipocytes,29 they may contribute to mesenteric 
mesenchymal abnormalities in Crohn’s disease [see below]. To inves-
tigate this possibility, the fibrocyte percentage in peripheral blood 
mononuclear cells [called the fibrocyte percentage] was measured in 
Cohort B. Peripheral venous samples were obtained from patients in 
Cohort B [n = 15] and healthy controls [n = 16]. Cells were stained 
for Collagen-I and CD45 [Supplementary Methods, available at 
ECCO-JCC online].30–32 All analysis was done on a BD FACSVerse 
[BD Biosciences] using BD FACSuite v1.0.5 [BD Biosciences]. 
Fibrocyte levels were displayed as a percentage of the total white 
blood cell population.
2.5. Immunohistochemical characterisation of 
mesenteric CD45+αSMA+ fibrocytes
Tissue myofibrocytes can be immunohistochemically identified by 
dual staining for CD45 and alpha smooth muscle actin [αSMA].33–35 
The distribution of CD45+αSMA+ cells was immunohistochemi-
cally examined in normal and in diseased mesentery in patients in 
Cohort B [n = 5] [Supplementary Methods, available at ECCO-JCC 
online]. All reviews were conducted by a pathologist and the princi-
pal investigator.
2.6. Statistical analyses
Data are presented as mean ± standard deviation [SD]. Pearson’s 
correlation coefficient was used to determine correlations between 
mesenteric, mucosal, and systemic parameters using SPSSv22 
[SPSS Inc., Chicago, USA]. A  two-tailed t-test was used to com-
pare parametric variables, and a Mann-Whitney U test was utilized 
for non-parametric comparisons. Chi-square tests and Z-tests for 
proportions were used to compare nominal data. To determine the 
relationship between fat wrapping and surgical recurrence, data 
were analysed using SPSSv22 and were presented as mean ± stand-
ard deviation and odds ratio [OR] with 95% confidence interval 
[CI]; ‘n’ represented the number of patients included in the analysis. 
Kaplan-Meier estimates and logistic regression analysis were per-
formed to determine recurrence-free survival in both cohorts and 
the association between fat wrapping and surgical disease recur-
rence. Fisher’s exact test was used to determine correlation between 
categorical variables, and continuous variables were assessed using 
analysis of variance. A  5% level of significance was used for all 
statistical tests.
3. Results
3.1. Clinical findings
3.1.1. Inclusion of the mesentery as part of intestinal resection 
is associated with reduced surgical recurrence
Cumulative reoperation rates were compared between patients who 
underwent a standard ileocolic resection [i.e. mesentery excluded] 
for Crohn’s disease [cohort A] and those undergoing a resection 
in which mesentery was also resected [Cohort B]. One patient in 
Cohort B [2.9% of total cohort] required reoperation for a Crohn’s-
related indication. Nine patients in Cohort A [30%] required reop-
eration for a Crohn’s-related indication. Three patients [10%] in 
Cohort A required reoperation for a Crohn’s-related indication on 
more than one occasion. Overall, 12 reoperations for a Crohn’s 
disease-related indication were required in Cohort A. The cumula-
tive rate of reoperation in Cohort A  was 40% [Figure  1G]. The 
majority [92%] of all reoperations occurred within 24  months 
[12.0 ± 10.15 months] of the preceding operation. The mean length 
of resected intestine, in surgical specimens, trended towards being 
greater in Cohort A  [33.3  ±  15.77  cm versus 28.6  ±  10.99  cm, 
p  =  0.198, t-test]. Lymph node yield was greater in specimens in 
Cohort B [12.25 ± 13 versus 2.4 ± 2.9, p = 0.002, t-test]. Distribution 
of known risk factors for surgical recurrence [i.e. active smoking, 
disease duration, age of diagnosis, family history, and disease loca-
tion] were similar between groups [Table  2]. A  greater number 
of patients had a history of smoking in Cohort A [Table 2]. On a 
multivariable analysis of factors known to predict surgical recur-
rence in Crohn’s disease, retention of the mesentery [i.e. mesentery 
not included in the resection] was an independent predictor of 
recurrence requiring surgical intervention [p  =  0.007] [Table  3]. 
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Figure 2. Key: FW refers to fat wrapping, MT refers to mesenteric thickening. [A] Digitally sculpted mesentery and intestinal tract demonstrating fat wrapping 
and mesenteric thickening. In mild mesenteric disease, thickening was confined to adipovascular regions. Fat wrapping commenced at the intestinal margin 
of the mesentery and was limited. In moderate mesenteric disease, adipovascular thickening was more pronounced but pedicles could still be differentiated. 
Fat wrapping increased but covered less than 25% of the bowel circumference. In severe mesenteric disease, thickening was pan-mesenteric. Adipovascular 
pedicles could not be differentiated. Fat wrapping extended beyond 25% of the circumference. [B–D] Macroscopic features of mesenteric (fat wrapping [B], 
mesenteric thickening [C]) and mucosal disease [D], as seen in postoperative surgical specimens. [E] Kaplan-Meier estimates demonstrating the percentage of 
patients reoperation-free following surgery for Crohn’s disease. Patients were subdivided into cohorts with and without fat wrapping of greater than 50% of the 
intestinal circumference at the index operation.
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Smoking at time of surgery and phenotype [as per the Vienna clas-
sification] were also predictors of surgical recurrence [p  =  0.010, 
p = 0.048, respectively] [Table 3].
3.1.2. Mesenteric and mucosal disease were topographically linked
As the mesentery was included in all resections in Cohort B, the topo-
graphic relationship between mesenteric and mucosal abnormalities 
was characterised. In all specimens examined, mucosal and mesen-
teric disease were topographically coupled [Supplementary Figure 1, 
available at ECCO-JCC online]. A short transition [the mesenteric 
transition zone] occurred between regions of normal and diseased 
mesentery [Figure 1C, D]. A corresponding mucosal transition zone 
occurred in adjacent mucosa [Figure 1E, F]. The severity of mucosal 
and mesenteric abnormalities increased in tandem. Mucosal oedema, 
polyposis, and aphthous ulceration occurred adjacent to mild or 
moderate mesenteric disease. Their distribution was limited to the 
mesenteric pole of the intestinal circumference. Confluent mucosal 
ulceration, stricture, and fistulas occurred  adjacent regions of severe 
mesenteric disease.
In all patients in Cohort B, the ileal resection [i.e. proximal] mar-
gin was placed immediately proximal to the mesenteric transition 
zone. When this approach was adopted, the proximal mucosal mar-
gin was histologically normal [i.e. not inflamed] in 84% of patients. 
In Cohort A, placement of the proximal resection was guided by 
surface intestinal rather than mesenteric parameters. In this cohort, 
mucosal inflammation occurred at the proximal margin in 79% of 
resection specimens.
3.1.3. Mesenteric, mucosal, and Crohn’s disease activity indices 
correlated
Mesenteric, mucosal, and Crohn’s disease activity indices were deter-
mined for patients in Cohort B. The mesenteric disease activity index 
correlated with the CDAI [r = 0.7, p <0.0001] and mucosal disease 
activity index [r  = 0.76, p  <0.0001]. The mucosal disease activity 
index and CDAI correlated [r  =  0.68, p  =  0.001]. Smoking was 
associated with an increase in the mesenteric disease activity index 
[4.5 ± 1.41 versus 3.0 ± 1.41, for smokers and non-smokers respect-
ively, p = 0.041, Mann-Whitney U test]. Smoking was not associated 
with an increase in the mucosal or Crohn’s disease activity index.
3.1.4. Advanced mesenteric disease predicted increased surgical 
recurrence
In Cohort C, fat wrapping was observed in 13 [41.9%] index 
resection specimens, and 18 [72%] recurrence specimens. Fat 
wrapping was associated with: stricture formation [p  =  0.036] 
but not with transmural inflammation [p = 1.0]; fissuring ulcera-
tion [p  =  0.255]; granuloma [p  =  0.373]; increased body mass 
index [p = 0.314]; histological neuronal hyperplasia [p = 0.287]; 
or fistula formation [p = 0.193] [Supplementary Table 2, available 
at ECCO-JCC online]. On univariable analysis [Supplementary 
Table 3, available at ECCO-JCC online], both penetrating (hazard 
ratio [HR] 3.8, 95% CI: 1.3–10.6, p = 0.012) and non-penetrat-
ing phenotype [HR 0.38, 95% CI: 0.15–0.98, p = 0.045], as well 
as fat wrapping [HR 4.5, 95% CI: 1.77–11.5, p = 0.002], were 
associated with surgical recurrence. On multivariable analysis 
[Table 4], only fat wrapping increased the risk of surgical recur-
rence [HR 4.7, 95% CI: 1.71–13.01, p  =  0.003]. Fat wrapping 
was associated with a shortened time to recurrence [Figure  2E, 
p <0.001].
3.2. Histological findings
3.2.1. Mesenteric mesenchymal abnormalities in Crohn’s 
disease
Surface mesothelium, submesothelial connective tissue, and con-
nective tissue septations were examined in regions of normal and 
diseased mesentery [Figure 3A]. The surface mesothelium/connect-
ive tissue complex was 24 ± 13 µm in width in normal mesentery 
[Figure  3B, left]. In Crohn’s disease, the complex thickened in a 
graduated manner in mild [62  ±  16 µm, p  <0.001, t-test], mod-
erate [215 ± 70 µm, p <0.001, t-test], and severe mesenteric dis-
ease [408 ± 73 µm, p <0.001, t-test] [Figure 3B, right]. Connective 
tissue septa followed the same pattern, increasing stepwise from 
16 ± 7 µm [normal], to 53 ± 17 µm [p <0.001, t-test], 101 ± 21 µm 
[p  <0.001, t-test], and 245  ±  100  µm [p  <0.001, t-test] in mild, 
moderate, and severe mesenteric disease, respectively [Figure 3B, 
C, and E]. Adipocytes numbered 23 ± 6 per HPF in normal mes-
entery [Figure 3C]. Adipocyte numbers increased in mild [28 ± 4/
HPF, p = 0.02, t-test], moderate [37 ± 7/HPF, p <0.001, t-test], and 
severe [60 ± 7/HPF, p  <0.001, t-test] mesenteric disease, respect-
ively [Figure 3E].
The intestinal hilum [i.e. where mesentery and adjacent intes-
tine intersect] was examined. In normal mesentery, a distinct intes-
tinal serosa occurred between mesentery and longitudinal muscle 
layers [Figure  3D; Supplementary Figure  3A, available at ECCO-
JCC online]. In Crohn’s disease, a distinct serosa was not evident 
[Figure 3F, Supplementary Figure 3B]. At the intersection between 
the mesentery and intestine, mesenteric mesenchymal abnormalities 
continued into adjacent longitudinal muscle and deeper intestinal 
layers [Figure 3F, Supplementary Figure 3B].
3.2.2. Mesenteric mesenchymal changes correlated with the 
percentage of circulating fibrocytes
Mesenteric mesenchymal [i.e. fibrotic and adipose] abnormali-
ties could be explained by changes in circulating and tissue-based 
fibrocytes. The circulating fibrocyte percentage was significantly 
increased in Crohn’s disease compared with healthy controls 
[8.0 ± 5.64 vs. 2.6 ± 1.68%, p = 0.003] [Figure 4A, B]. The circulat-
ing fibrocyte percentage was similar in Crohn’s disease and other 
inflammatory bowel conditions requiring surgery [8.0  ±  5.64 
vs. 5.7 ± 4.28, p = 0.656] [Figure 4B]. The circulating fibrocyte 
percentage decreased 4 weeks after intestinal and mesenteric 
Table 1A. Mesenteric disease activity index in Crohn’s disease [see 
Figure 2]. 
Mesenteric disease score Severity Stage Score
FW minimal, MT minimal Mild One 1
FW <25%, MT adipovascular 
pedicle only
Moderate I Two A 2
FW <25%, pan-mesenteric MT Moderate II Two B 4
FW >25%, pan-mesenteric MT Severe Three 6
FW, fat wrapping; MT, mesenteric thickening.
Table  1B. Intestinal disease activity index. For each feature pre-
sent, points were attributed. The final score was the sum of all 
points accumulated.
Intestine Scores
Oedema 1
Aphthous ulcer 2
Confluent ulcer 3
Stricture 4
Fistula 5
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resection [5.7 ± 2.12% vs. 1.7 ± 1.20%, p = 0.005] [Figure 4C], 
when levels were similar to healthy controls [1.7  ±  1.20% vs. 
2.6 ± 1.68%, p = 0.1]. The circulating fibrocyte percentage cor-
related with the CDAI [r = 0.87, p = 0.009] as well as with mes-
enteric [r = 0.81] and mucosal [r = 0.77] disease activity indices.
CD45+αSMA+ fibrocytes were not identified in normal mesen-
tery. In Crohn’s mesentery, they were readily identifiable both in 
and nearby mesenteric vessels [arrows, Figure  4D; Supplementary 
Figure  4A, B, available at ECCO-JCC online] and in clusters at 
the intestinal surface [arrows, Figure  4E]. In adjacent intestine, 
CD45+αSMA+ fibrocytes were identifiable in the connective tissue 
septa of the outer muscle layers [Figure 4E and insets].
4. Discussion
Recent advances have made it possible to examine the mesentery and 
its role in disease in a systematic manner.1,2 This study evaluated the 
role of the mesentery in ileocolic Crohn’s disease. First, rates of surgi-
cal recurrence [defined as recurrence requiring surgical intervention] 
were compared between patients who underwent a conventional 
ileocolic resection [i.e. the mesentery was retained] versus those in 
whom the mesentery was also resected. The surgical recurrence rate 
was significantly reduced in the latter group. In addition, intestinal 
length and margin positivity rates were both reduced while nodal 
yield was increased, following mesenteric resection. To quantify and 
Table  2. Demographics of Cohorts A  and B.  Ileocolic resection for Crohn’s disease. Where stated, anti-tumour necrosis factor [TNF] 
medication consists of Humira® or infliximab. Data are presented as mean ± standard deviation [SD]. 
Variable Cohort A [n = 30] Cohort B [n = 34] p-Value
Gender 0.659 [overall chi2]
 Male 14 [47%] 14 [41%] 0.660 [Z-test]
 Female 16 [53%] 20 [59%] 0.660 [Z-test]
Age at diagnosis [years] 30.3 ± 11.93 28.0 ± 10.93 0.445 [t-test]
Age at index surgery [years] 37.7 ± 13.67 35.9 ± 11.87 0.574 [t-test]
Disease duration [months] 75.0 ± 117.42 70.7 ± 78.83 0.838 [MW-U]
Length of intestine resected [cm] 33.3 ± 15.77 28.6 ± 10.99 0.198 [t-test]
 Ileum 25.2 ± 15.71 22.1 ± 11.13 0.430 [t-test]
 Colon 9.9 ± 12.08 7.4 ± 5.55 0.383 [t-test]
Smoking status at index surgery 0.393 [overall chi2]
 Active 14 [47%] 18 [53%] 0.617 [Z-test]
 History 6 [20%] 2 [6%] 0.089 [Z-test]
 Non-smoker 9 [30%] 13 [38%] 0.490 [Z-test]
 Data unavailable 1 [3%] 1 [3%] 0.928 [Z-test]
Family history 0.437 [overall chi2]
 Yes 8 [27%] 12 [35%] 0.459 [Z-test]
 No 19 [63%] 21 [62%] 0.897 [Z-test]
 Data unavailable 3 [10%] 1 [3%] 0.246 [Z-test]
Medications at time of index surgery 24 [80%] 27 [79%] 0.878 [overall Chi2]
 Anti-inflammatory 15 [50%] 9 [27%] 0.151 [Chi2 test]
 Steroid 13 [43%] 12 [35%] 0.752 [Chi2 test]
 Immunosuppressant 11 [37%] 10 [29%] 0.766 [Chi2 test]
 Biologic 5 [17%] 15 [44%] 0.043 [chi2 test]
 None 5 [17%] 5 [15%] 0.878 [chi2 test]
 Data unavailable 1 [3%] 2 [6%] 0.878 [chi2 test]
Prophylactic medication after index surgery 6 [20%] 7 [21%] 0.166 [overall chi2]
 Imuran® 4 [13%] 3 [9%] 0.125 [chi2 test]
 6MP 0 [0%] 1 [3%] 0.117 [chi2 test]
 Anti-TNF 2 [7%] 4 [12%] 0.150 [chi2 test]
 None 19 [63%] 26 [76%] 0.166 [chi2 test]
 Data unavailable 5 [17%] 1 [3%] 0.166 [chi2 test]
Vienna Classification
Age at diagnosis 0.875 [overall chi2]
 A1 <40 years old 23 [77%] 26 [76%] 0.984 [Z-test]
 A2 ≥40 years old 6 [20%] 6 [18%] 0.810 [Z-test]
 Data unavailable 1 [3%] 2 [6%] 0.631 [Z-test]
Location 0.257 [overall chi2]
 L1 terminal ileum 23 [77%] 26 [76%] 0.984 [Z-test]
 L2 colonic 2 [6%] 0 [0%] 0.126 [Z-test]
 L3 ileocolic 5 [17%] 6 [18%] 0.920 [Z-test]
 L4 upper GI 0 [0%] 2 [6%] 0.177 [Z-test]
Disease phenotype 0.040 [overall chi2]
 B1 non-stricturing, non-penetrating 16 [53%] 8 [24%] 0.014 [Z-test]
 B2 stricturing 6 [20%] 14 [41%] 0.069 [Z-test]
 B3 penetrating 8 [27%] 12 [35%] 0.459 [Z-test]
Bold text indicates statistically significant results. Italicised text indicates results for overall statistical tests.
MW-U, MannWhitney U test; 6MP, 6-mercaptopurine; GI, gastrointestinal.
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compare mesenteric disease, an activity index was developed that 
correlated with mucosal and Crohn’s disease activity indices, and 
worsened significantly with smoking. Advanced mesenteric disease 
[i.e. fat wrapping] independently predicted surgical recurrence and 
reduced time to recurrence.
The above findings lend support to inclusion of mesentery in 
resections for ileocolic Crohn’s disease. Several authors previously 
proposed that mesenteric inclusion would lead to improved out-
comes by increasing the volume of lymphatic tissue removed.6–8 The 
present findings support this, as lymph node harvest was greater fol-
lowing mesenteric inclusion. Lack of take-up of mesenteric resection 
is explained by the fact that the mesentery bleeds extensively during 
division, and that radical resection is technically challenging due to 
Crohn’s-related complications.36 Trials aiming to further investigate 
the suggestion [i.e. that the mesentery be included in ileocolic resec-
tion] are increasingly required and are aided by recent clarification 
of mesenteric anatomy.1–3,26–28,37,38 They are further prompted by the 
findings of the present study which found that conventional ileocolic 
resection [in which the mesentery was retained] was a predictor of 
surgical recurrence.
Positioning of the proximal intestinal division remains a topic of 
debate in Crohn’s disease.6,7,9,24,36,39–43 The present study is the first 
to describe a mesenteric and mucosal transition zone where both 
types of disease manifestation were topographically coupled. When 
the mesenteric transition zone was used to guide placement of the 
proximal intestinal division, the proximal margin was non-inflamed 
in the majority of patients. Mesenteric disease features can also be 
used to aid in the assessment of disease activity and identification of 
patients at increased risk of surgical recurrence. The severity of mes-
enteric disease correlated with mucosal disease and with the Crohn’s 
disease activity index. Fat wrapping greater than 50% independently 
predicted increased rates of recurrence requiring reoperation.
One of the main questions arising from this study is whether the 
mesentery should be included as part of resection for patients undergo-
ing surgery for ileocolic Crohn’s disease. Some suggest that mesenteric 
abnormalities such as fat wrapping are immunologically protect-
ive.44–50 If this relationship held, then radical mesenteric resection could 
lead to poorer [rather than improved] clinical outcomes. During stric-
turoplasty, the mesentery is retained. Notwithstanding this, mucosal 
healing is observed in regions that have undergone stricturoplasty.51–53 
These findings suggest that the mesentery may be retained. However, 
rates of surgical recurrence following stricturoplasty are variable, and 
often high, with a mean and median of 28% and 26%, respectively.51–64 
In many instances, repeat surgery is required at or near the site of pre-
vious stricturoplasty.55,56,63,64 It is difficult to reconcile mucosal healing 
with high rates of repeat surgery, unless other non-mucosal [e.g. mesen-
teric] factors are determinants of recurrence requiring reoperation after 
stricturoplasty. Whether this is the case after stricturoplasty or not, is 
an important question that arises from the present study.
The cumulative rate of surgical recurrence in Cohort A, i.e. 
patients undergoing conventional resection for ileocolic Crohn’s 
disease, was 40%. This rate is relatively high, as rates of surgical 
recurrence range from 4% to 60%.14,16,18,20,39,65–78 Low rates of sur-
gical recurrence have been quoted for conventional [i.e. mesentery-
sparing] resection.65–68,79 In general however, the mean and median 
rates of surgical recurrence following conventional surgery [i.e. 21% 
and 17.6%, respectively,] are such that patients are mostly cautioned 
that the possible requirement for reoperation is significant. That said, 
mesenteric resection adds to the radicality of intestinal surgery and, 
if it is possible to avoid this, then one should. Multi-institutional tri-
als will be required to determine whether mesenteric-based or mes-
enteric-sparing approaches are best suited to different geographical 
cohorts of patients diagnosed with ileocolic Crohn’s disease.
The question also arises as to how inclusion of the mesentery 
could lead to improved outcomes following resection in patients with 
ileocolic Crohn’s disease. The present study demonstrated that in ile-
ocolic Crohn’s disease, mesenteric mesenchymal abnormalities extend 
into the outer layers of adjacent intestine. This may partially explain 
the transmural appearance of Crohn’s disease. Mesenteric excision 
could reduce mesenteric mesenchymal inputs and in this manner lead 
to improved outcomes. As removal of the mesentery is associated 
with a greater lymphadenectomy [compared with that observed in 
conventional resection], it is feasible that removal reduces immuno-
logical inputs, thereby leading to improved postoperative outcomes. 
Mesenteric resection may also interrupt local recruitment of fibro-
blast precursors, i.e. fibrocytes.80 These can differentiate into either 
adipocytes or fibroblasts.29 The present study found that the fibrocyte 
percentage in circulating white cells was increased in Crohn’s disease, 
normalised following surgical resection, and correlated with mesen-
teric disease severity. The immunohistochemical findings indicate that 
fibrocytes are recruited to the mesentery in which they migrate to the 
intestinal surface. Fibrocyte recruitment to the intestinal surface may 
be interrupted by inclusion of the mesentery in the resection.
The present study is limited in that it compares relatively small-
sized prospective and historical cohorts. Although this approach has 
been used previously,81 it is subject to bias that could be obviated in 
a randomised control trial. However, the magnitude of the differ-
ence in surgical recurrence rates between Cohorts A and B suggests 
that this cannot be fully explained as a type 2 error. In addition, a 
randomised controlled trial has recently been completed, examining 
outcomes after inclusion of the mesentery in resections for Crohn’s 
Table 3. Multivariable analysis of association between known fac-
tors of surgical recurrence and development of recurrence requir-
ing surgical intervention.
Variable Univariable  
analysis [p-value]
Multivariable  
analysis [p-value]
Gender 1.000
Smoking at time of surgery 0.015 0.010
Age at diagnosis 0.934
Disease phenotype 0.029 0.048
Disease location 0.469
Age at surgery 0.788
Non-mesenteric resection 0.004 0.007
Duration of disease 0.584
Duration of follow-up 0.363
Bold text indicates statistically significant results. 
Table  4. Multivariable analysis of association between clinico- 
histopathological features and development of recurrence 
requiring surgical intervention.
Variable HR 95% CI P-value
Non-stricturing/non-penetrating 
phenotype
0.764 0.241–2.428 0.649
Penetrating phenotype 2.729 0.772–9.649 0.119
Fat wrapping 4.722 1.713–13.017 0.003
Bold text indicates statistically significant results. 
HR, hazard ratio; CI, confidence interval.
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Figure 3. [A] [Left] Digital sculpture demonstrating the junction between the small intestinal mesentery and the right mesocolon, and [right] mesenteric connective 
tissue lattice [grey]. [B] [Left] Photomicrograph (haematoxylin and eosin [H&E]) demonstrating normal mesentery, surface mesothelium [single arrow], and 
connective tissue [4X]. A  connective tissue septation [double arrows] extended from the submesothelial connective tissue. [Right] H&E photomicrograph 
demonstrating mesentery in Crohn’s disease [4X]. The surface mesothelium, submesothelial [single arrow], and interlobular connective tissue were thickened 
[multiple arrows]. [C] H&E photomicrograph demonstrating interface between normal mesentery and longitudinal muscle of adjacent intestine [4X]. The 
connective tissue serosa [arrows] separated mesentery from longitudinal muscle. The serosa was continuous with mesenteric connective tissue and extended 
into the outer longitudinal circular layer [asterix]. [D] Scanning electron microscopic [SEM] photomicrograph demonstrating mesentery, serosa [arrows], and 
adjacent intestine, in normality [30X]. [E] H&E photomicrograph demonstrating serosal thickening in a region of fat wrapping in Crohn’s disease [asterix] [10X]. 
[F] SEM photomicrograph demonstrating mesentery, serosa [arrows], and adjacent intestine, in Crohn’s disease [45X]. Mesenteric connective tissue thickening 
extended into the intestinal longitudinal muscle.
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disease [Yi Li, personal communication].82 Preliminary analyses of 
the trial data point to a reduction in postoperative recurrence of 
Crohn’s disease, when the mesentery is included as part of intestinal 
resection. A further limitation of the present study relates to the fact 
that the mesenteric and mucosal disease activity indices have not 
been formally validated. However, both correlated with the CDAI, 
and the mesenteric disease score worsened with active smoking.
In summary, our study suggests that adoption of mesenteric-
based strategies is associated with improved clinical outcomes after 
ileocolic resection in Crohn’s disease. Mesenchymal inputs contribute 
to mesenteric abnormalities and their reduction may partly explain 
the benefits of mesenteric-based surgical strategies. Mesenteric mes-
enchymal inputs may provide novel cellular and molecular targets 
for future pharmaco-therapeutic interventions in Crohn’s disease.
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